Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | INMT | O95050 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5961657 | 0.89 | KDM4E (0.51) | KDM4ELMNAINMTGBA1NPC1 | |
| SCHEMBL7180702 | 0.89 | KDM4E (0.51) | KDM4ELMNAINMTGBA1NPC1 | |
| SCHEMBL5961659 | 0.89 | KDM4E (0.51) | KDM4ELMNAINMTGBA1NPC1 | |
| SCHEMBL11218039 | 0.73 | KDM4E (0.39) | KDM4ELMNAGBA1 | |
| SCHEMBL8681593 | 0.70 | KDM4E (0.37) | KDM4ELMNA | |
| SCHEMBL8681594 | 0.70 | KDM4E (0.37) | KDM4ELMNA | |
| SCHEMBL16178828 | 0.69 | KDM4E (0.71) | KDM4ELMNAGBA1NPC1ALDH1A1 | |
| SCHEMBL3269126 | 0.69 | KDM4E (0.41) | KDM4ELMNAGBA1 | |
| SCHEMBL2593142 | 0.67 | KDM4E (0.97) | KDM4ELMNANPC1ALDH1A1MAPT | |
| SCHEMBL7179841 | 0.67 | KDM4E (0.51) | KDM4ELMNAGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008033351-A2 | MULTIMODAL ABUSE RESISTANT AND EXTENDED RELEASE FORMULATIONS | THERAQUEST BIOSCIENCES, INC. (US) | 2008-03-20 | — | — | WO | claimed |
| WO-2008024490-A2 | ORAL PHARMACEUTICAL FORMULATIONS OF ABUSE DETERRENT CANNABINOIDS AND METHOD OF USE | THERAQUEST BIOSCIENCES, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| CN-108276358-B | N-arylamidine substituted trifluoroethyl sulfide derivatives as acaricides and insecticides | 拜尔农作物科学股份公司 | 2021-11-02 | — | — | CN | disclosed |
| US-10051861-B2 | N-arylamidine-substituted trifluoroethyl sulfide derivatives as acaricides and insecticides | BAYER CROPSCIENCE AG (DE) | 2018-08-21 | — | — | US | disclosed |
| US-9642363-B2 | N-arylamidine-substituted trifluoroethyl sulfide derivatives as acaricides and insecticides | BAYER CROPSCIENCE AG (DE) | 2017-05-09 | — | — | US | disclosed |
| US-20170057914-A1 | N-ARYLAMIDINE-SUBSTITUTED TRIFLUOROETHYL SULFIDE DERIVATIVES AS ACARICIDES AND INSECTICIDES | BAYER CROPSCIENCE AG | 2017-03-02 | — | — | US | disclosed |
| US-20140315898-A1 | N-ARYLAMIDINE-SUBSTITUTED TRIFLUOROETHYL SULFIDE DERIVATIVES AS ACARICIDES AND INSECTICIDES | BAYER CROPSCIENCE AG (DE) | 2014-10-23 | — | — | US | disclosed |
| WO-2008033351-A2 | MULTIMODAL ABUSE RESISTANT AND EXTENDED RELEASE FORMULATIONS | THERAQUEST BIOSCIENCES, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008027442-A2 | ABUSE DETERRENT ORAL PHARMACEUTICAL FORMULATIONS OF OPIOID AGONISTS AND METHOD OF USE | THERAQUEST BIOSCIENCES, LLC (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008024490-A2 | ORAL PHARMACEUTICAL FORMULATIONS OF ABUSE DETERRENT CANNABINOIDS AND METHOD OF USE | THERAQUEST BIOSCIENCES, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| US-20030207865-A1 | Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents | DIXON BRIAN R (US) | 2003-11-06 | — | — | US | disclosed |
| US-6353006-B1 | TREATMENT OF BONE DISORDERS, OSTEOPOROSIS AND HEALING AGENT | BAYER CORPORATION | 2002-03-05 | — | — | US | disclosed |
| CN-1337955-A | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents | AMERICAN BAYER CORP (US) | 2002-02-27 | — | — | CN | disclosed |
| EP-1144396-A2 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | Bayer Corporation (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042031-A3 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | BAYER AG (US) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000042031-A2 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315898-A1 | N-ARYLAMIDINE-SUBSTITUTED TRIFLUOROETHYL SULFIDE DERIVATIVES AS ACARICIDES AND INSECTICIDES | AFF4, ARSA, AFF1 | KDM4E 1809/4885LMNA 4138/4885INMT 1630/4885 |
| US-20030207865-A1 | Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents | PGR, PGRMC2, PGRMC1 | KDM4E 2157/4885LMNA 3221/4885INMT 1586/4885 |
| US-10051861-B2 | N-arylamidine-substituted trifluoroethyl sulfide derivatives as acaricides and insecticides | AFF4, AFF1, ARSA | KDM4E 1829/4885LMNA 4259/4885INMT 1615/4885 |
| US-20170057914-A1 | N-ARYLAMIDINE-SUBSTITUTED TRIFLUOROETHYL SULFIDE DERIVATIVES AS ACARICIDES AND INSECTICIDES | AFF4, ARSA, AFF1 | KDM4E 1809/4885LMNA 4138/4885INMT 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.